ACLF, acute-on-chronic liver failure; AKI, acute kidney injury; ARR, absolute risk reduction; AVB, acute variceal bleeding; Ascites; BNP, brain natriuretic peptide; BRTO, balloon-occluded retrograde transvenous obliteration; Bleeding; CHF, chronic heart failure; CLD, chronic liver disease; CSPH, clinically significant portal hypertension; Cirrhosis; EVL, endoscopic variceal ligation; GOV, gastro-oesophageal varices; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; HVPG, hepatic venous pressure gradient; Haemorrhage; ICA, International Club of Ascites; IGV, isolated gastric varices; INR, international normalised ratio; ISMN, isosorbide mononitrate; LVP+A, LVP with albumin; LVP, large-volume paracenteses; MELD, model for end-stage liver disease; NNT, number needed to treat; NSBB, non-selective beta blocker; OS, overall survival; PCI, percutaneous coronary intervention; PFTE, polytetrafluoroethylene; PLT, platelet count; PSE, portosystemic encephalopathy; PV, portal vein; PVT, portal vein thrombosis; Portal hypertension; Portal vein thrombosis; RA, refractory ascites; RCTs, randomised controlled trials; SBP, spontaneous bacterial peritonitis; SEMS, self-expandable metallic stent; TFS, transplant-free survival; TIPS, transjugular intrahepatic portosystemic shunt; Transjugular intrahepatic portosystemic shunt